vTv Therapeutics Inc. (VTVT)
VTVT Stock Price Chart
Explore vTv Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze VTVT price movements and trends.
VTVT Company Profile
Discover essential business fundamentals and corporate details for vTv Therapeutics Inc. (VTVT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Jul 2015
Employees
26.00
Website
https://www.vtvtherapeutics.comCEO
Paul J. Sekhri
Description
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
VTVT Financial Timeline
Browse a chronological timeline of vTv Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.97, while revenue estimate is $333.33k.
Earnings released on 13 May 2026
EPS came in at $1.65 surpassing the estimated $0.34 by +385.29%, while revenue for the quarter reached $36.84m , beating expectations by +84.20%.
Earnings released on 10 Mar 2026
EPS came in at -$0.58 surpassing the estimated -$0.98 by +40.82%.
Earnings released on 6 Nov 2025
EPS came in at -$1.08 falling short of the estimated -$0.97 by -11.34%.
Earnings released on 12 Aug 2025
EPS came in at -$0.92 falling short of the estimated -$0.85 by -8.24%.
Earnings released on 15 May 2025
EPS came in at -$0.77 falling short of the estimated -$0.73 by -5.48%.
Earnings released on 20 Mar 2025
EPS came in at -$0.55 surpassing the estimated -$0.87 by +36.78%, while revenue for the quarter reached $17.00k .
Earnings released on 12 Nov 2024
EPS came in at -$0.88 surpassing the estimated -$3.60 by +75.56%.
Earnings released on 8 Aug 2024
EPS came in at -$0.81 surpassing the estimated -$3.20 by +74.69%.
Earnings released on 9 May 2024
EPS came in at -$1.17 surpassing the estimated -$3.20 by +63.44%, while revenue for the quarter reached $1.00m .
Earnings released on 13 Mar 2024
EPS came in at -$1.67 surpassing the estimated -$2.80 by +40.36%, while revenue for the quarter reached -$9.00k .
Stock split effective on 21 Nov 2023
Shares were split 1 : 40 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Nov 2023
EPS came in at -$3.20 matching the estimated -$3.20.
Earnings released on 11 Aug 2023
EPS came in at -$2.80 falling short of the estimated -$0.07 by -3.90k%, while revenue for the quarter reached $9.00k .
Earnings released on 11 May 2023
EPS came in at -$2.40 surpassing the estimated -$3.20 by +25.00%.
Earnings released on 6 Mar 2023
EPS came in at -$2.40 matching the estimated -$2.40, while revenue for the quarter reached $9.00k .
Earnings released on 10 Nov 2022
EPS came in at -$2.00 matching the estimated -$2.00.
Earnings released on 15 Aug 2022
EPS came in at -$1.60 surpassing the estimated -$4.00 by +60.00%, while revenue for the quarter reached $9.00k .
Earnings released on 12 May 2022
EPS came in at -$4.00 falling short of the estimated -$3.20 by -25.00%, while revenue for the quarter reached $2.00m .
Earnings released on 29 Mar 2022
EPS came in at -$3.20 matching the estimated -$3.20, while revenue for the quarter reached $9.00k , missing expectations by -98.20%.
Earnings released on 9 Nov 2021
EPS came in at -$0.80 surpassing the estimated -$2.80 by +71.43%, while revenue for the quarter reached $3.00m , beating expectations by +130.77%.
Earnings released on 4 Aug 2021
EPS came in at -$0.40 surpassing the estimated -$2.80 by +85.71%, while revenue for the quarter reached $9.00k , meeting expectations.
VTVT Stock Performance
Access detailed VTVT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
